Category Archives: Mesenchymal Stem Cells

PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:08:01More inPeople Blogs Read more from the original source: PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video … Continue reading →

Public release date: 6-Nov-2012 [ | E-mail | Share ] Contact: Jill Scoggins jill.scoggins@louisville.edu 502-852-7461 University of Louisville LOS ANGELES Marked sustained improvement in all patients with zero adverse effects. For a phase I clinical trial, these results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital today reported just such almost-never-attained data. In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks. They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration new heart tissue replacing former dead tissue killed by heart attack. "The … Continue reading →

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:09:00More inPeople Blogs Continued here: PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video … Continue reading →

Public release date: 6-Nov-2012 [ | E-mail | Share ] Contact: Steve Goodyear sgoodyear@mhif.org 952-807-8365 Minneapolis Heart Institute Foundation MINNEAPOLIS, MN November 6, 2012 Administering autologous stem cells obtained from bone marrow either 3 or 7 days following a heart attack did not improve heart function six months later, reports a new clinical trial supported by the National Institutes of Health. The results of this trial, called TIME (Transplantation In Myocardial Infarction Evaluation), were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation Tuesday, Nov. 6, at the 2012 Scientific Sessions of the American Heart Association in Los Angeles. The results of this trial mirror a previous, related study (LateTIME) which found that autologous bone marrow stem cell therapy given 2-3 weeks after a heart attack did not improve cardiac recovery. Both TIME and LateTIME were carried out by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute. "The data presented by TIME do much to advance stem cell therapy research," said Jay Traverse, MD of the Minneapolis Heart Institute Foundation and Principal Investigator of this study. "While this study did not provide a demonstrated cardiac benefit after six months, … Continue reading →

MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country. Stem cell treatment involves the use of adult stem cells to treat a range of diseases. The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens. The regulation of laboratories and practitioners involves five key points. First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses. Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence. Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy. "Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go. … Continue reading →

Washington, November 7 (ANI): Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital. In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks. They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack. "The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in … Continue reading →

April Flowers for redOrbit.com Your Universe Online Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients. The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects. Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session. The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans. The trial shows the feasibility of isolating and expanding autologous stem cells … Continue reading →

RIO DE JANEIRO--(BUSINESS WIRE)-- CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses. Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz. ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1. Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after … Continue reading →

Stem cells harvested from the bone marrow of healthy donors proved as effective as those derived from the patients themselves, a study found Of 30 people that had previously suffered a heart attack, half were treated with their own stem cells and half with cells from donors In both groups scar tissue was reduced by 33 per cent Researchers say the use of donor cells could speed up treatment By Kerry Mcdermott PUBLISHED: 14:51 EST, 6 November 2012 | UPDATED: 05:58 EST, 7 November 2012 Stem cells culled from the bone marrow of healthy donors work as well as cells harvested from patients themselves as a treatment for damaged hearts, research has revealed. The 13-month trial compared the safety and effectiveness of stem cells derived from the bone marrow of patients themselves to those provided by donors in the treatment of people suffering the after-effects of a heart attack. The donor stem cells proved as effective as the patient stem cells in reducing scar tissue - a result researchers called 'very, very significant'. Scientists are now exploring the use of stem cells to treat heart disease and other ailments (file photo) Researchers have said the discovery that donor cells are … Continue reading →

J. Hare - Comparison of Allogen vs Autolog Mesenchymal Stem Cells in Pts. with Ischemic CMP J. Hare - Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy POSEIDON - This trial was designed to test the safety and efficacy of allogeneic vs. autologous mesenchymal stem cells in patients with ischemic cardiomyopathy. Annual Session of the American Heart Association November 5, 2012, Los AngelesFrom:CardioletterViews:0 0ratingsTime:08:37More inScience Technology Read this article: J. Hare - Comparison of Allogen vs Autolog Mesenchymal Stem Cells in Pts. with Ischemic CMP - Video … Continue reading →